Arcturus Therapeutics (ARCT) said Monday it started dosing patients with cystic fibrosis and ornithine transcarbamylase deficiency in phase 2 multiple ascending dose studies in December 2024.
Patients in the phase 2 cystic fibrosis study are expected to get daily treatments of ARCT-032 over a 28-day period, according to the company.
Patients with ornithine transcarbamylase deficiency will receive five intravenous infusions of ARCT-810 over two months and the first participant in the US received 0.5 milligrams per kilogram dose in December.
The company expects phase 2 interim data for both program in H1.
Arcturus shares were up more than 6% in regular trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。